Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Diab Vasc Dis Res. 2013 Jan;10(1):93-6. doi: 10.1177/1479164112444640. Epub 2012 May 4.
Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm(2) in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm(2), the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.
替米沙坦部分激活过氧化物酶体增殖物激活受体 γ（PPARγ），这可能改善内脏脂肪组织的堆积，并改善胰岛素作用。19 例原发性高血压合并代谢综合征患者被随机分为每天服用 40mg 替米沙坦（TELMI 组）或 80mg 缬沙坦（VAL 组），治疗 24 周。用计算机断层扫描（CT）测量的内脏脂肪面积（VFA）在 TELMI 组从 150.4±15.5cm²显著减少至 127.7±16.7cm²（p=0.049）。虽然 VAL 组的 VFA 也从 169.8±14.8cm²减少至 155.3±14.8cm²，但变化不显著（p=0.173）。两组在体重、体重指数（BMI）、腰围、皮下脂肪面积（SFA）、空腹血糖和稳态模型评估的胰岛素抵抗（HOMA-IR）与基线和随访数据相比均无显著变化。总之，与缬沙坦相比，替米沙坦可能有益于减少内脏脂肪组织。
